Albert Cha

Managing Partner at Vivo Capital LLC

Albert Cha

Albert Cha

Managing Partner at Vivo Capital LLC

Overview
Career Highlights

Vivo Capital LLC

RelSci Relationships

935

Number of Boards

25

Birthday

1973

Age

45

Relationships
RelSci Relationships are individuals Albert Cha likely has professional access to. A relationship does not necessarily indicate a personal connection.

President, Chief Executive Officer & Director at Minerva Surgical, Inc.

Relationship likelihood: Strong

Co-Founder at KalVista Pharmaceuticals Ltd.

Relationship likelihood: Strong

General Partner at Interwest Venture Management Co.

Relationship likelihood: Strong

Co-Founder at Nexeption LLC

Relationship likelihood: Strong

Founder, Managing Partner at Nexeption LLC

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Menlo Therapeutics, Inc.

Relationship likelihood: Strong

Managing Member at TP Management VII LLC

Relationship likelihood: Strong

Former President & Chief Executive Officer at KalVista Pharmaceuticals, Inc.

Relationship likelihood: Strong

Board Director & Chairman, Audit Committee at AlterG, Inc.

Relationship likelihood: Strong

Co-Founder at Ascendis Pharma A/S

Relationship likelihood: Strong

Paths to Albert Cha
Potential Connections via
Relationship Science
You
Albert Cha
Managing Partner at Vivo Capital LLC
Education
M.S. in Electrical Engineering

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

Ph.D. in Neuroscience

The University of California, Los Angeles School of Medicine known as the David Geffen School of Medicine at UCLA, is an accredited medical school located in Los Angeles, California, USA.

Ph.D Neuroscience

UCLA's primary purpose as a public research university is the creation, dissemination, preservation and application of knowledge for the betterment of our global society. To fulfill this mission, UCLA is committed to academic freedom in its fullest terms: We value open access to information, free and lively debate conducted with mutual respect for individuals, and freedom from intolerance. In all of our pursuits, we strive at once for excellence and diversity, recognizing that openness and inclusion produce true quality. These values underlie our three institutional responsibilities. Learning and teaching at UCLA are guided by the belief that undergraduate, graduate and professional school students and their teachers belong to a community of scholars. This community is dedicated to providing students with a foundational understanding of a broad range of disciplines followed by the opportunity for in-depth study in a chosen discipline. All members of the community are engaged together in discovering and advancing knowledge and practice. Learning occurs not only in the classroom but also through engagement in campus life and in communities and organizations beyond the university.

Memberships
Member
Current

Alpha Omega Alpha supports many programs for medical students and physicians at our 123 chapters, and publishes a quarterly journal, The Pharos, which contains articles on nontechnical medical subjects, including history, ethics, national issues, personal essays, and poetry.

Career History
Managing Partner
2005 - Current

Vivo Ventures invests in US-based companies with therapeutic products in clinical development. Although they focus on companies with later-stage products, the firm is willing to work with companies (and their founders) that may not have significant infrastructure. They invest in companies with promising products at all financing stages (Series A to public companies) and work closely with founders and management to complete the development and commercial launch of those products and achieve a successful exit. When considering investments, Vivo Ventures emphasizes the following criteria: (1) the quality of the company's underlying technology, including supporting preclinical and clinical data (2) the market potential of the company's products (3) the strength of the company's intellectual property and (4) the strength of the company's management team.

Investor
Current

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Investor
Current

YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada.

Boards & Committees
Independent Director
2017 - Current

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Independent Director
2015 - Current

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.

Member, Board of Directors
2014 - Current

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Political Donations
$2,700
2015

Representative from Indiana's 5th Congressional District

$5,000
2012

Representative from Indiana's 5th Congressional District

$5,000
2011

Representative from Indiana's 5th Congressional District

Investments
Details Hidden

Acura Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary aversion and impede technologies. It operates its business through the research, development, and manufacture of innovative abuse deterrent, orally administered pharmaceutical products. The company was founded in 1935 and is headquartered in Palatine, IL.

Details Hidden

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Details Hidden

YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Albert Cha. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Albert Cha's profile does not indicate a business or promotional relationship of any kind between RelSci and Albert Cha.